esketamine – Medxy AI

Assessing Nearly Five Years of Real-World Safety Data on Esketamine Nasal Spray in the United States

By MedXY 10/30/2025

A comprehensive evaluation of nearly five years of esketamine nasal spray use confirms its safety profile consistent with clinical trials, with no new safety signals detected in over 1.4 million treatment sessions.

news Psychiatry Specialties

Esketamine Monotherapy for Treatment-Resistant Depression: A New Therapeutic Frontier

By MedXY 09/11/2025

A phase 4 randomized trial demonstrates that esketamine nasal spray monotherapy significantly reduces depressive symptoms in adults with treatment-resistant depression, offering a promising alternative to oral antidepressants.

Oncology Psychiatry Specialties

Esketamine in Lung Cancer Patients with Major Depression: Efficacy for Smoking Cessation and Treatment-Resistant Depression

By MedXY 08/25/2025

This review synthesizes evidence from a randomized trial and real-world studies showing esketamine's efficacy and safety in smoking cessation among lung cancer patients with MDD, as well as in treatment-resistant depression, highlighting cognitive benefits and long-term safety.